BioLineRx Ltd.
BLRX
$4.24
-$0.33-7.22%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -97.83% | 137.69% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -97.83% | 137.69% | |||
| Cost of Revenue | -99.44% | 640.75% | |||
| Gross Profit | -96.10% | 37.35% | |||
| SG&A Expenses | -85.80% | 0.32% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -82.26% | 44.42% | |||
| Operating Income | 24.57% | 41.15% | |||
| Income Before Tax | 260.87% | 45.26% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 260.87% | 45.26% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 260.87% | 45.26% | |||
| EBIT | 24.57% | 41.15% | |||
| EBITDA | -15.34% | 57.55% | |||
| EPS Basic | 195.83% | 51.02% | |||
| Normalized Basic EPS | 255.56% | 70.00% | |||
| EPS Diluted | 195.83% | 51.02% | |||
| Normalized Diluted EPS | 255.56% | 70.00% | |||
| Average Basic Shares Outstanding | 69.54% | 9.05% | |||
| Average Diluted Shares Outstanding | 69.54% | 9.05% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||